Hospira (HSP -5.7%) takes a hit today after posting better-than-expected Q4 results, but issuing...
Wednesday, February 13, 2:14 PM ETHospira (HSP -5.7%) takes a hit today after posting better-than-expected Q4 results, but issuing a disappointing outlook for FY13. Net earnings swung to a profit amid stronger sales of its specialty drugs and the impact of a major write-down in the prior-year period, but the company warns that FY13 will be burdened by ongoing heavy costs to resolve regulatory concerns over manufacturing at some of its plants. It now expects to earn between $2.05 to $2.20 on net sales growth of 1% to 3%, below estimates of $2.31 on revenue growth of 4%.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles